FindTrial
Sign In

Retrospective analysis of the correlation between serum interleukin-6 and tumor markers targeted therapy in EGFR mutation-positive non-small cell lung cancer

Retrospective analysis of the correlation between serum interleukin-6 and tumor markers targeted therapy in EGFR mutation-positive non-small cell lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046643
Enrollment
Unknown
Registered
2021-05-24
Start date
2021-05-24
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Case series:Nil

Sponsors

Daping Hospital, Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 87 Years

Inclusion criteria

Inclusion criteria: 1.Patients with histologically-confirmed advanced EGFR-mutant NSCLC who had been treated with first-line EGFR-TKIs; 2.Patients with baseline blood IL-6 levels were included.

Exclusion criteria

Exclusion criteria: 1.Patients with unknown mutational status; 2.Confirmed bacterial infection; 3.Those without response evaluation.

Design outcomes

Primary

MeasureTime frame
Therapeutic Evaluation;—

Countries

China

Contacts

Public ContactLi Li

Daping Hospital, Army Medical University

lili10119@126.com+86 23 68757780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026